TIXAGEVIMAB/CILGAVIMAB Protection of Covid-19 in Transplanted Patients

首次发布于 2022 年 2 月 10 日

Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19

计划入组 82 人 · 首次发布于 2023 年 8 月 8 日

Non-inferiority Trial on Treatments in Early COVID-19

计划入组 536 人 · 首次发布于 2022 年 4 月 11 日

Cilgavimab/Tixagevimab

Cilgavimab(Evusheld)

AZD-5156

Invivyd's Pemgarda Shows Continued Neutralizing Activity Against SARS-CoV-2 Variant XEC

FDA Revokes Emergency Use Authorizations for COVID-19 Antibody Treatments Evusheld and REGEN-COV

FDA Authorizes AstraZeneca's Evusheld for COVID-19 Prevention in Immunocompromised Individuals